Similar significant joint effects of ALT > 40 U/L with NAFLD, liver cirrhosis, HBV and HCV infection, and any one of these CLDs were observed in insulin, and non-insulin users. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.